Track topics on Twitter Track topics that are important to you
Vical is developing gene-based pharmaceutical products for human therapy. Vical's patented naked DNA gene delivery technology and proprietary lipids are designed to deliver selected genes into some cells in the body. These genes have been shown in clinical trials to cause the cells to produce desired proteins which may prevent or treat infectious and malignant diseases and other disorders. Vical is developing cancer product candidates internally while developing vaccines for infectious diseases and gene-based delivery of therapeutic proteins for other disorders primarily in collaboration with corporate partners.
10390 Pacific Center Court
United States of America
Vical Inc. and AnGes Inc. are teaming up once again, this time for a chronic hepatitis B virus treatment.
A number of other equities research analysts have also issued reports on the stock. HC Wainwright set a $9.00 target price on shares of Vical and gave the company a "buy" rating in a research note on ...
Vical Inc. (infectious disease therapies) netted $23.3mm through a public offering of 7mm common shares at $1.75 and 7.2mm pre-funded warrants at $1.74. Proceeds will support clinical trial expenses r...
- Astellas expects topline results in 1Q2018 SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the last patient completed their final assessment duri...
SAN DIEGO, CA / ACCESSWIRE / August 8, 2017 / Vical Incorporated (NASDAQ: VICL) will host a live webcast to discuss the results of the second quarter 2017, to be held Tuesday, August 8, 2017, 2017 ...
Vical Incorporated Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Vical Incorporated Mergers Acquisitions MA, Partnerships Alliances and Investments repo...
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the last patient completed their final assessment during the one year follow-up period in the mu...
SAN DIEGO, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2017. Net loss for the third quarter of 201...
Vical is developing gene-based pharmaceutical products for human therapy. Vical's patented naked DNA gene delivery technology and proprietary lipids are designed to deliver selected genes into some ce...
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applica...
Inovio Biomedical Corporation (AMEX: INO) is a leader in cancer and other medical therapies using electroporation-enabled delivery of useful biopharmaceuticalsInovio Biomedical Corporation (AMEX: INO)...
We have published hundreds of Vical news stories on BioPortfolio along with dozens of Vical Clinical Trials and PubMed Articles about Vical for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vical Companies in our database. You can also find out about relevant Vical Drugs and Medications on this site too.
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...